
Pediatric Dermatologist, DERM360 | Medical Director, Pediatric Skin Research | Miami, Florida, USA

Consultant Pediatric Allergist at the Department of Pediatrics of the University of Padova, Italy

Professor of Medicine and Pediatrics; Chief of Clinical and Translational Research, University of South Florida, Tampa, United States

Professor at the University of Montreal and Sainte-Justine University Medical Centre at the Department of Pediatrics, Dermatology Division, Quebec, Canada

Janie Robinson and John Moore Lee Chair of Pediatrics and Director of Center for Pediatric Asthma Research | Vanderbilt University, Tennessee, United States

Chair of Pediatric Allergy-Immunology at the National Jewish Health, Professor of Pediatrics at the University of Colorado Denver School of Medicine, US

Professor of Medicine | Associate Professor of Pediatrics in the Maternal and Child Health Department | Sapienza University of Rome; Consultant Pediatric Gastroenterologist | Umberto I University Hospital, Rome, Italy

Professor of Pediatrics | Perelman School of Medicine, University of Pennsylvania; Chief of Allergy Section and Director of the Center for Pediatric Eosinophilic Disorders | Children’s Hospital of Philadelphia, Pennsylvania, United States
Carolina Gutiérrez Junquera, MD, PhD, is an associate professor of Pediatrics at the Universidad Autónoma of Madrid, Spain, and a consultant pediatric gastroenterologist at University Hospital Puerta de Hierro Majadahonda in Madrid.

Chief of the Division of Pediatric Gastroenterology and Hepatology of the First Department of Pediatrics | National and Kapodistrian University of Athens; Head of the Gastroenterology Department | Children’s Hospital Agia Sofia, Athens, Greece

This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Eulàlia Baselga reviewing the systemic treatment landscape for children under 12 years of age with AD in the EU. Dr. Baselga also discusses the latest clinical data on the use of baricitinib in pediatric patients aged 2 to 17 years, and both clinical and real-world data on the efficacy and safety of dupilumab in pediatric patients with AD aged as young as 6 months.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.